The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2852-2863

  Feng, Xiao Jun ^a   Gao, Hui ^a,b   Gao, Si ^a   Li, Zhuoming ^a   Li, Hong ^a   Lu, Jing ^a   Wang, Jiao Jiao ^a   Huang, Xiao Yang ^a   Liu, Min ^a   Zou, Jian ^c   Ye, Jian Tao ^a   Liu, Pei Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b JISHOU UNIVERSITY   (China)

^c CHENGDU FIFTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ISOPRENALINE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR RECEPTOR NOR1; ORPHAN NUCLEAR RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; DNA BINDING PROTEIN; NERVE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NR4A3 PROTEIN, RAT; PARP1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE SILENCING; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SURFACE AREA; ANIMAL; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE TARGETING; GENETICS; IMMUNOPRECIPITATION; METABOLISM; UPREGULATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE KNOCK-IN TECHNIQUES; GENE KNOCKDOWN TECHNIQUES; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; ISOPROTERENOL; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RNA, MESSENGER; SYMPATHOMIMETICS; UP-REGULATION;

EID: 84929208385     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13091     Document Type: Article

References (49)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Ame JC, Spenlehauer C, de Murcia G, (2004). The PARP superfamily. Bioessays 26: 882-893.
4. Bartha E, Kiss GN, Kalman E, Kulcsar G, Kalai T, Hideg K, et al. (2008a). Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J Cardiovasc Pharmacol 52: 253-261.
5. Bartha E, Kiss GN, Kalman E, Kulcsar G, Kalai T, Hideg K, et al. (2008b). Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J Cardiovasc Pharmacol 52: 253-261.
6. Blander G, Guarente L, (2004). The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435.
7. Cheng Z, Volkers M, Din S, Avitabile D, Khan M, Gude N, et al. (2011). Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. Eur Heart J 32: 2179-2188.
8. Decker P, Miranda EA, de Murcia G, Muller S, (1999). An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications. Clin Cancer Res 5: 1169-1172.
9. Frey N, Katus HA, Olson EN, Hill JA, (2004). Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589.
10. Hamers AA, Hanna RN, Nowyhed H, Hedrick CC, de Vries CJ, (2013). NR4A nuclear receptors in immunity and atherosclerosis. Curr Opin Lipidol 24: 381-385.
11. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
12. Kraus WL, (2008). Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 20: 294-302.
13. Liu M, Li Z, Chen GW, Li ZM, Wang LP, Ye JT, et al. (2014). AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy. Mol Cell Endocrinol 392: 14-22.
14. Luo X, Kraus WL, (2012). On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26: 417-432.
15. Martinez-Gonzalez J, Badimon L, (2005). The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res 65: 609-618.
16. Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L, (2003a). Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ Res 92: 96-103.
17. Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L, (2003b). Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ Res 92: 96-103.
18. Maxwell MA, Muscat GE, (2006). The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal 4: e2.
19. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
20. Mitsuyama S, Takeshita D, Obata K, Zhang GX, Takaki M, (2013). Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats. J Mol Cell Cardiol 59: 95-106.
21. Myers SA, Eriksson N, Burow R, Wang SC, Muscat GE, (2009). Beta-adrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues. Mol Cell Endocrinol 309: 101-108.
22. Oh KS, Lee S, Yi KY, Seo HW, Koo HN, Lee BH, (2009). A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia. J Pharmacol Exp Ther 328: 10-18.
23. Ohkura N, Nagamura Y, Tsukada T, (2008). Differential transactivation by orphan nuclear receptor NOR1 and its fusion gene product EWS/NOR1: possible involvement of poly(ADP-ribose) polymerase I, PARP-1. J Cell Biochem 105: 785-800.
24. Ozakca I, Arioglu-Inan E, Esfahani H, Altan VM, Balligand JL, Kayki-Mutlu G, et al. (2013). Nebivolol prevents desensitization of beta-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond beta1-adrenoceptor blockage. Am J Physiol Heart Circ Physiol 304: H1267-H1276.
25. Pacher P, Szabo C, (2007). Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25: 235-260.
26. Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, et al. (2006). PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol 41: 149-159.
27. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
28. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P, (2005). Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem 280: 29256-29262.
29. Petrucco S, (2003). Sensing DNA damage by PARP-like fingers. Nucleic Acids Res 31: 6689-6699.
30. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP, (2005). Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 288: H486-H496.
31. Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP, (2006). Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 291: H1545-H1553.
32. Pols TW, Bonta PI, de Vries CJ, (2007). NR4A nuclear orphan receptors: protective in vascular disease? Curr Opin Lipidol 18: 515-520.
33. Ponnio T, Conneely OM, (2004). nor-1 regulates hippocampal axon guidance, pyramidal cell survival, and seizure susceptibility. Mol Cell Biol 24: 9070-9078.
34. Ponnio T, Burton Q, Pereira FA, Wu DK, Conneely OM, (2002). The nuclear receptor Nor-1 is essential for proliferation of the semicircular canals of the mouse inner ear. Mol Cell Biol 22: 935-945.
35. Putt KS, Hergenrother PJ, (2004). An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. Anal Biochem 326: 78-86.
36. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, et al. (2009). SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 29: 4116-4129.
37. Ruwhof C, van der Laarse A, (2000). Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 47: 23-37.
38. Schreiber V, Dantzer F, Ame JC, de Murcia G, (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
39. Szabo C, (2005). Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol Res 52: 34-43.
40. Szabo G, Liaudet L, Hagl S, Szabo C, (2004). Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 61: 471-480.
41. Szanto M, Brunyanszki A, Kiss B, Nagy L, Gergely P, Virag L, et al. (2012). Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. Cell Mol Life Sci 69: 4079-4092.
42. Tessem JS, Moss LG, Chao LC, Arlotto M, Lu D, Jensen MV, et al. (2014). Nkx6.1 regulates islet beta-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proc Natl Acad Sci U S A 111: 5242-5247.
43. Virag L, Szabo C, (2002). The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429.
44. Wang RH, He JP, Su ML, Luo J, Xu M, Du XD, et al. (2013). The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Mol Med 5: 137-148.
45. Wansa KD, Harris JM, Muscat GE, (2002). The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. J Biol Chem 277: 33001-33011.
46. Yoshida T, Yamashita M, Horimai C, Hayashi M, (2014). Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity. J Biol Chem 289: 26107-26118.
47. Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, et al. (2013). Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br J Pharmacol 168: 117-128.
48. Zhao Y, Howatt DA, Gizard F, Nomiyama T, Findeisen HM, Heywood EB, et al. (2010). Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ Res 107: 501-511.
49. Zhou SG, Zhou SF, Huang HQ, Chen JW, Huang M, Liu PQ, (2006). Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats. J Proteome Res 5: 2901-2908.